New Strong Sell Stocks for May 11th
ADMA, APTV and ASTE have been added to the Zacks Rank #5 (Strong Sell) List on May 11th, 2026.
ADMA Q1 EPS Jumps 73% Y/Y, Revenues Slip, 2026 View Down
ADMA cuts its 2026 outlook after Q1 revenues slip amid IG market pressure, though Asceniv demand and margins stay strong.
ADMA Biologics, Inc. (ADMA) Q1 2026 Earnings Call Transcript
ADMA Biologics, Inc. (ADMA) Q1 2026 Earnings Call Transcript
Will the Label Expansion of Asceniv Boost ADMA's Top-Line Growth?
ADMA stock in focus after FDA expands Asceniv's label to younger patients, boosting market reach and growth outlook amid rising demand.
Andrew Sather: Why Some Stock Buybacks Are Basically “Putting Money on Fire”
Stock buybacks have become one of the most misunderstood tools in corporate finance.
3 Biotech Stocks to Watch for Respectable Growth Beyond AI
Artificial intelligence has dominated investor attention for two years, but biotech revenue lines are also bending sharply higher.
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
ADMA vs. Takeda: surging Asceniv demand boosts ADMA, but Takeda's diversified portfolio and stronger returns make it the steadier pick now.
Will Asceniv Deliver for ADMA in the Upcoming Quarterly Results?
ADMA banks on surging Asceniv demand to sustain growth, supported by expanded plasma supply and broader coverage, which should drive continued gains into 2026.
Does ADMA Biologics' Growth Story Outweigh Short-Seller Concerns?
ADMA stock slides after a short report sparks volatility, but management pushes back, citing strong Asceniv demand and steady fundamentals.
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
Adma Biologics (ADMA) reached $10.65 at the closing of the latest trading day, reflecting a +1.53% change compared to its last close.
ADMA Crashes 42.5% YTD: Right Time to Buy the Stock?
ADMA stock plunges after a short report, but strong Asceniv demand, rising revenues, and margin expansion signal potential recovery ahead.
